- The approval is based on P-lll COAST-X study assessing Taltz (80mg, q4w) vs PBO for the treatment of adult patients with nr-axSpA with objective signs of inflammation for 52wks.
- Result: 1EPs of ASAS40 @16wks. (35% vs 19%); ASAS40 response @52wks. (30% vs 13%), met its 2EPs, showing efficacy in reducing disease activity and sacroiliac joint inflammation, improving patient function & QoL, the safety profile is consistent with the previous study
- Taltz is a mAb that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor
Click here to read full press release/ article | Ref: Newswire Canada | Image: Everyday Health